brentuximab vedotin + bendamustine + anti-PD-1 antibody

This is a combination therapy comprising three agents: **brentuximab vedotin** (an antibody-drug conjugate targeting CD30), **bendamustine** (an alkylating agent with partial purine analog activity), and an **anti-PD-1 antibody** (such as nivolumab or pembrolizumab, monoclonal antibodies that block the programmed death-1 pathway). This regimen is under investigation for treating relapsed or refractory classical Hodgkin lymphoma (R/R cHL). The rationale is to leverage the cytotoxic and immunomodulatory activity of bendamustine, the targeted antineoplastic effect of brentuximab vedotin, and the immune checkpoint inhibition provided by anti-PD-1 antibodies, aiming for synergistic efficacy. The combination has been reported to demonstrate high response rates and manageability in toxicity, with promising results in both adult and pediatric heavily pretreated lymphoma patients[1][3][5][7][8][9].

Brand names

Adcetris (brentuximab vedotin)None specific for the combination

Other names

BVB + anti-PD-1brentuximab vedotin, bendamustine, and anti-PD-1 antibody combination